Template:Serotonin receptor modulators: Difference between revisions
Content deleted Content added
m Reduce WP:PEIS (transcluded on Alcohol (drug)) (via WP:JWB) |
m bypass redirect to LSD |
||
| Line 30: | Line 30: | ||
* [[Eltoprazine]] |
* [[Eltoprazine]] |
||
* [[Enciprazine]] |
* [[Enciprazine]] |
||
* [[Ergoline]]s (e.g., [[bromocriptine]], [[cabergoline]], [[dihydroergotamine]], [[ergotamine]], [[lisuride]], [[ |
* [[Ergoline]]s (e.g., [[bromocriptine]], [[cabergoline]], [[dihydroergotamine]], [[ergotamine]], [[lisuride]], [[LSD]], [[Methylergometrine|methylergometrine (methylergonovine)]], [[methysergide]], [[pergolide]]) |
||
* [[F-11,461]] |
* [[F-11,461]] |
||
* [[F-12826]] |
* [[F-12826]] |
||
| Line 154: | Line 154: | ||
* [[CP-135807]] |
* [[CP-135807]] |
||
* [[CP-286601]] |
* [[CP-286601]] |
||
* [[Ergoline]]s (e.g., [[bromocriptine]], [[cabergoline]], [[dihydroergotamine]], [[ergotamine]], [[ |
* [[Ergoline]]s (e.g., [[bromocriptine]], [[cabergoline]], [[dihydroergotamine]], [[ergotamine]], [[LSD]], [[methysergide]]) |
||
* [[GR-46611]] |
* [[GR-46611]] |
||
* [[L-694247]] |
* [[L-694247]] |
||
| Line 250: | Line 250: | ||
* [[DOx]] (e.g., [[2,5-Dimethoxy-4-bromoamphetamine|DOB]], [[2,5-Dimethoxy-4-chloroamphetamine|DOC]], [[2,5-Dimethoxy-4-iodoamphetamine|DOI]], [[2,5-Dimethoxy-4-methylamphetamine|DOM]]) |
* [[DOx]] (e.g., [[2,5-Dimethoxy-4-bromoamphetamine|DOB]], [[2,5-Dimethoxy-4-chloroamphetamine|DOC]], [[2,5-Dimethoxy-4-iodoamphetamine|DOI]], [[2,5-Dimethoxy-4-methylamphetamine|DOM]]) |
||
* [[Efavirenz]] |
* [[Efavirenz]] |
||
* [[Ergoline]]s (e.g., [[1P-LSD]], [[ALD-52]], [[bromocriptine]], [[cabergoline]], [[ergine|ergine (LSA)]], [[ergometrine|ergometrine (ergonovine)]], [[ergotamine]], [[lisuride]], [[Lysergic acid 2,4-dimethylazetidide|LA-SS-Az]], [[Lysergic acid 2-butyl amide|LSB]], [[ |
* [[Ergoline]]s (e.g., [[1P-LSD]], [[ALD-52]], [[bromocriptine]], [[cabergoline]], [[ergine|ergine (LSA)]], [[ergometrine|ergometrine (ergonovine)]], [[ergotamine]], [[lisuride]], [[Lysergic acid 2,4-dimethylazetidide|LA-SS-Az]], [[Lysergic acid 2-butyl amide|LSB]], [[LSD]], [[LSD-Pip]], [[Lysergic acid hydroxyethylamide|LSH]], [[Lysergic acid 3-pentyl amide|LSP]], [[Methylergometrine|methylergometrine (methylergonovine)]], [[pergolide]]) |
||
* [[Flumexadol]] |
* [[Flumexadol]] |
||
* [[IHCH-7113]] |
* [[IHCH-7113]] |
||
| Line 399: | Line 399: | ||
* [[Dimemebfe]] |
* [[Dimemebfe]] |
||
* [[DOx]] (e.g., [[2,5-Dimethoxy-4-bromoamphetamine|DOB]], [[2,5-Dimethoxy-4-chloroamphetamine|DOC]], [[2,5-Dimethoxy-4-iodoamphetamine|DOI]], [[2,5-Dimethoxy-4-methylamphetamine|DOM]]) |
* [[DOx]] (e.g., [[2,5-Dimethoxy-4-bromoamphetamine|DOB]], [[2,5-Dimethoxy-4-chloroamphetamine|DOC]], [[2,5-Dimethoxy-4-iodoamphetamine|DOI]], [[2,5-Dimethoxy-4-methylamphetamine|DOM]]) |
||
* [[Ergoline]]s (e.g., [[ALD-52]], [[cabergoline]], [[dihydroergotamine]], [[Ergine|ergine (LSA)]], [[ergotamine]], [[lisuride]], [[Lysergic acid 2,4-dimethylazetidide|LA-SS-Az]], [[Lysergic acid 2-butyl amide|LSB]], [[ |
* [[Ergoline]]s (e.g., [[ALD-52]], [[cabergoline]], [[dihydroergotamine]], [[Ergine|ergine (LSA)]], [[ergotamine]], [[lisuride]], [[Lysergic acid 2,4-dimethylazetidide|LA-SS-Az]], [[Lysergic acid 2-butyl amide|LSB]], [[LSD]], [[LSD-Pip]], [[Lysergic acid hydroxyethylamide|LSH]], [[Lysergic acid 3-pentyl amide|LSP]], [[pergolide]]) |
||
* [[Flumexadol]] |
* [[Flumexadol]] |
||
* [[Lorcaserin]] |
* [[Lorcaserin]] |
||
| Line 575: | Line 575: | ||
| list1 = |
| list1 = |
||
* ''Agonists:'' [[Ergoline]]s (e.g., [[2-Bromo-LSD|2-Br-LSD (BOL-148)]], [[ergotamine]], [[ |
* ''Agonists:'' [[Ergoline]]s (e.g., [[2-Bromo-LSD|2-Br-LSD (BOL-148)]], [[ergotamine]], [[LSD]]) |
||
* [[Serotonin|Serotonin (5-HT)]] |
* [[Serotonin|Serotonin (5-HT)]] |
||
* [[Substituted tryptamine|Tryptamines]] (e.g., [[5-Carboxamidotryptamine|5-CT]]) |
* [[Substituted tryptamine|Tryptamines]] (e.g., [[5-Carboxamidotryptamine|5-CT]]) |
||
| Line 596: | Line 596: | ||
| list1 = |
| list1 = |
||
* ''Agonists:'' [[Ergoline]]s (e.g., [[dihydroergocryptine]], [[dihydroergotamine]], [[ergotamine]], [[lisuride]], [[ |
* ''Agonists:'' [[Ergoline]]s (e.g., [[dihydroergocryptine]], [[dihydroergotamine]], [[ergotamine]], [[lisuride]], [[LSD]], [[mesulergine]], [[metergoline]], [[methysergide]]) |
||
* [[Hypidone]] |
* [[Hypidone]] |
||
* [[Serotonin|Serotonin (5-HT)]] |
* [[Serotonin|Serotonin (5-HT)]] |
||
| Line 650: | Line 650: | ||
* [[Bifeprunox]] |
* [[Bifeprunox]] |
||
* [[E-55888]] |
* [[E-55888]] |
||
* [[Ergoline]]s (e.g., [[ |
* [[Ergoline]]s (e.g., [[LSD]]) |
||
* [[LP-12]] |
* [[LP-12]] |
||
* [[LP-44]] |
* [[LP-44]] |
||
Revision as of 18:27, 19 May 2024
This template's initial visibility currently defaults to collapsed, meaning that it is hidden apart from its title bar.
To change this template's initial visibility, the |state= parameter may be used:
{{Serotonin receptor modulators|state=expanded}}will show the template expanded, i.e. fully visible.{{Serotonin receptor modulators|state=autocollapse}}will show the template autocollapsed, i.e. if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar, but if not, it is fully visible.